NPPB and fibrosis: Compared to mice receiving doxorubicin alone, mice receiving empagliflozin treatment before doxorubicin exhibited better cardiac contractility (Figure 1A), decreased DNA damage (Figure 1B), less cardiac fibrosis (Figure 1C), decreased cardiomyocyte damage (Figure 1D) as well as lower expression levels of BNP (brain natriuretic peptide) (Figure 1E) and Col1a1 (collagen type I, α 1) (Figure 1F) mRNAs.